CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 103 filers reported holding CHINOOK THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,984,927 | +4155.4% | 77,692 | +2464.1% | 0.02% | – |
| Q1 2023 | $70,145 | -91.6% | 3,030 | -90.5% | 0.00% | -100.0% |
| Q4 2022 | $835,466 | -28.6% | 31,888 | -46.4% | 0.01% | -28.6% |
| Q3 2022 | $1,170,000 | -58.2% | 59,501 | -62.8% | 0.01% | -58.8% |
| Q2 2022 | $2,799,000 | +10266.7% | 160,059 | +9600.5% | 0.02% | – |
| Q1 2022 | $27,000 | -97.1% | 1,650 | -97.1% | 0.00% | -100.0% |
| Q4 2021 | $937,000 | +3246.4% | 57,451 | +2785.5% | 0.01% | – |
| Q2 2021 | $28,000 | +366.7% | 1,991 | +425.3% | 0.00% | – |
| Q4 2020 | $6,000 | – | 379 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $198,319,737 | 34.81% |
| Saturn V Capital Management LP | 524,811 | $20,163,239 | 11.18% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $166,956,377 | 9.97% |
| Altium Capital Management LP | 305,000 | $11,718,100 | 8.87% |
| MPM BioImpact LLC | 1,003,406 | $38,550,859 | 7.76% |
| Affinity Asset Advisors, LLC | 321,017 | $12,333,473 | 4.31% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,131,000 | $81,873,020 | 3.69% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,748,141 | $67,163,577 | 3.59% |
| Nan Fung Group Holdings Ltd | 113,950 | $4,377,959 | 2.80% |
| Vivo Capital, LLC | 934,879 | $35,918,051 | 2.48% |